Medical Dialogues4d
Risankizumab improves long-term outcomes in patients with palmoplantar pustulosis: Study
A new study published in The Journal of Dermatology revealed that patients with palmoplantar pustulosis (PPP) who were 18 ...
Dermatology Advisor4d
Risankizumab May Be Superior to Other Biologic Therapies in Plaque Psoriasis
Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.
Healio6d
Extended treatment with Skyrizi ‘may ultimately benefit’ refractory Crohn’s disease
Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi ...
MedPage Today10d
Risankizumab Makes a Difference in Hard-to-Treat Psoriasis
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The IL-23 inhibitor risankizumab proved to be safe and efficacious after 52 weeks of treatment in patients with ...
pharmaphorum5d
AbbVie to file long-acting psoriasis contender
AbbVie’s psoriasis drug risankizumab has posted strong results in its latest phase 3 trial, as the company prepares to file the drug with global regulators. An interleukin-23 inhibitor ...